Every 10-Q that Option Care Health, Inc. (OPCH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OPCH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OPCH filings page.
Option Care Health delivered modest growth in the first half of 2026. For Q2, net revenue rose 1.9% to $1.44 billion, while gross margin slipped to 18.5% from 19.0% as therapy mix shifted. Net income increased 6.7% to $53.9 million, with diluted EPS of $0.35.
For the first six months, revenue reached $2.79 billion and net income $99.3 million. Operating cash flow strengthened sharply to $171.5 million, helped by a significant inventory reduction. The company invested $20.1 million in capital expenditures and did not close any acquisitions in 2026 to date.
Leverage remains meaningful, with total debt principal of $1.17 billion, but liquidity is supported by $193.8 million of cash and $846.0 million of available Revolver capacity. The company repurchased 7.9 million shares for $167.5 million in the first half, leaving $525.0 million authorized. Management highlights ongoing pressure in its chronic inflammatory disease portfolio and expects CID dynamics to reduce 2026 gross profit by about $55 million, partially offset by growth in acute and other higher-margin therapies.
Option Care Health reported steady Q1 2026 results, with net revenue of $1,350.7M, up slightly from $1,333.0M a year earlier. Net income was $45.3M versus $46.7M and diluted EPS rose to $0.29 from $0.28 as the share count declined.
Gross profit edged down to $262.0M and margin slipped to 19.4%, as strength in acute therapies was offset by pressure in chronic inflammatory disease treatments. Management now expects chronic inflammatory disease dynamics to reduce 2026 gross profit by about $55M.
The company ended the quarter with $177.3M in cash and expanded its revolving credit facility to $850.0M, leaving $846.0M available. It also repurchased 528,981 shares for $17.5M, with $675.0M remaining under its $1.0B authorization.
Option Care Health (OPCH) filed its Q3 2025 10‑Q, reporting solid growth with stable profitability. Net revenue rose to $1,435,016,000 from $1,278,546,000, up 12.2% year over year, driven by increased acute and chronic therapy volumes. Gross profit was $272,902,000 versus $256,749,000, while operating income held at $84,507,000. Net income was $51,816,000 compared with $53,856,000, and diluted EPS was $0.32 versus $0.31.
For the first nine months, revenue reached $4,184,073,000 and net income was $149,081,000. The company closed the Intramed Plus acquisition for $117,247,000 (net of cash), adding referral sources and trademarks and increasing goodwill. It refinanced its First Lien Term Loan, cutting the rate to Term SOFR plus 1.75% and extending maturity to September 22, 2032, and added $49,600,000 of incremental debt. Cash from operations was $222,556,000; cash ended at $309,822,000. OPCH repurchased 6,805,621 shares year‑to‑date for $212,500,000, with $287,500,000 remaining under its authorization. Shares outstanding were 160,108,000 as of September 30, 2025.